A diagnosis of acute myeloid leukaemia (AML) encompasses a wide range of prognoses, and it is important to attempt to classify each patient as accurately as possible within the disease continuum.

—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

The new classifications included several major changes and may help identify different subtypes. The fifth edition of the World Health Organization classification (2022 WHO) and the International ...

Abstract Over the last decades, significant advances have been made in the knowledge and treatment of acute myeloid leukemia (AML). The WHO has recognized this new information by incorporating into ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...

May 1, 2008 — New details of differences among patients with cytogenetically normal acute myeloid leukemia (AML), which appear to affect both clinical and treatment outcome, are described in 2 papers ...

Scientists have refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis. Compared to adult cancers, pediatric cancers often have ...

Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...

NATICK, Mass., March 3, 2026 /PRNewswire/ -- Pillar Biosciences today announced the launch of the oncoReveal ® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) ...

Masayuki Umeda, MD, PhD, left, Jeffery Klco, MD, PhD, center, and Jing Ma, PhD, right, of the Dept. of Pathology discuss the current World Health Organization classification of acute myeloid leukemia ...